Background Butyrate-producing gut bacteria are reduced in patients with active inflammatory
bowel disease (IBD), supporting the hypothesis that butyrate supplementation may be …

Background and Aims Vedolizumab is an anti-α4β7 antibody approved for the treatment of
ulcerative colitis [UC]. Although it is assumed that vedolizumab blocks intestinal homing of …

Background Personalized medicine requires finding relationships between variables that
influence a patient’s phenotype and predicting an outcome. Sparse generalized canonical …

… We determined the MaRIA 2 and simplified MaRIA (sMARIA) scores for each segment using
… Rodríguez: acquisition of data; Maria-Carme Masamunt: acquisition of data Elena Ricart: …

BACKGROUND Crohn’s disease (CD) is a chronic inflammatory bowel disorder that progresses
to bowel damage (BD) over time. An image-based index, the Lémann index (LI), has …

Background and Aims:Vedolizumab is an anti-α4β7 antibody approved for the treatment of
ulcerative colitis [UC]. Although it is assumed that vedolizumab blocks intestinal homing of …

Background and Aims: Ex vivo-generated autologous tolerogenic dendritic cells [tolDCs] can
restore immune tolerance in experimental colitis. The aim of this study was to determine the …

Background and Aims: Despite the negative results of blocking IL-17 in Crohn's disease (CD)
patients, selective modulation of Th17-dependent responses warrants further study. …

Background Haematopoietic stem cell transplantation [HSCT] is considered a therapeutic
option for patients with severe Crohn’s disease [CD] unresponsive to currently available …

… Unlike the original MaRIA score, the sMaRIA does not include gadolinium enhancement
as part of the components for assessing CD activity. Most MRE protocols include the use of …